Net Present ValueIf previously a $40 million PGX plant had a $100 million net present value what could the net present value of that same plant be later this year if the 10X 100L facility is successfully commissioned de-risking scale-up? The 100L facility will also allow for small-scale commercial production and revenue generation. PGX will have further been validated to small-scale commercial production.
What will the net present value of the $40 million plant be if CZO also signs a licensing deal validating PGX? The CoQ10 market appears multi-fold larger than the yeast beta glucan immune booster market. What would the net present value of a partnership in the CoQ10 space be worth. At the AGM Gilles said they were in talks with serious potential partners who understand bioavalability as a unique selling point. With the AEZS/CZO merger CZO could also have capital and additional internal capability to sign stronger PGX deals as it also looks at an immune booster opportunity. If $40 million was needed for an immune booster plant alone how much could be needed to further serve a CoQ10 partnership in the optimal partnership structure. A NASDAQ listing to support access to capital is now a near term need and the merger builds CZO's capital and internal capability.
PGX-YBG/fibrosis was also previously said to be a 6 month study from a full clinical trial 'go' decision. Avalyn raised C$80 million going into its Phase I human clinical trial.